Skip to main content
Erschienen in: Medical Oncology 8/2015

01.08.2015 | Original Paper

PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma

verfasst von: Yiwei Wang, Hang Wang, Qi Zhao, Yu Xia, Xiaoyi Hu, Jianming Guo

Erschienen in: Medical Oncology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

The incidence of kidney cancer has been increasing globally during the past two decades. Renal cell carcinoma (RCC) is the most aggressive subtype of kidney cancer, which usually deteriorates with epithelial–mesenchymal transition (EMT) that facilitates the migration and invasion of cancer cells. Till now, the underlying mechanism remains unclear. In this study, we demonstrated that programmed death ligand 1 (PD-L1/B7-H1/CD274) could induce EMT and enhance RCC cell cancer stemness through up-regulation of SREBP-1c. Furthermore, we found that PD-L1 is up-regulated in human RCC metastases. These results, taken together, provide evidence for a novel mechanism of PD-L1 in RCC progression, suggesting that there is a close relationship between EMT and immune escape signaling pathways in RCC.
Literatur
3.
Zurück zum Zitat Li P, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67(6):1134–41.PubMedCrossRef Li P, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67(6):1134–41.PubMedCrossRef
4.
Zurück zum Zitat Bianchi M, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–80.PubMedCrossRef Bianchi M, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–80.PubMedCrossRef
5.
Zurück zum Zitat Zhi WI, Kim JJ. An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res. 2014;1(2):1–10.PubMedCentralPubMedCrossRef Zhi WI, Kim JJ. An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res. 2014;1(2):1–10.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–47.PubMedCrossRef Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–47.PubMedCrossRef
7.
Zurück zum Zitat Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.PubMedCrossRef Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.PubMedCrossRef
8.
Zurück zum Zitat Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.PubMed Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.PubMed
9.
Zurück zum Zitat Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307–14.PubMedCrossRef Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307–14.PubMedCrossRef
10.
Zurück zum Zitat Al-Chaqmaqchi H, et al. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS One. 2013;8(4):e60367.PubMedCentralPubMedCrossRef Al-Chaqmaqchi H, et al. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS One. 2013;8(4):e60367.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Parsa AT, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–8.PubMedCrossRef Parsa AT, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–8.PubMedCrossRef
12.
Zurück zum Zitat Thompson RH, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5.PubMedCrossRef Thompson RH, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5.PubMedCrossRef
13.
Zurück zum Zitat Zeng Q, et al. CD146, an epithelial–mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA. 2012;109(4):1127–32.PubMedCentralPubMedCrossRef Zeng Q, et al. CD146, an epithelial–mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA. 2012;109(4):1127–32.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Medvedev SP, et al. OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells. Genetika. 2008;44(12):1589–608.PubMed Medvedev SP, et al. OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells. Genetika. 2008;44(12):1589–608.PubMed
15.
Zurück zum Zitat Adachi K, et al. Role of SOX2 in maintaining pluripotency of human embryonic stem cells. Genes Cells. 2010;15(5):455–70.PubMed Adachi K, et al. Role of SOX2 in maintaining pluripotency of human embryonic stem cells. Genes Cells. 2010;15(5):455–70.PubMed
16.
Zurück zum Zitat Rysman E, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70(20):8117–26.PubMedCrossRef Rysman E, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70(20):8117–26.PubMedCrossRef
17.
18.
Zurück zum Zitat Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–45.PubMedCrossRef Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–45.PubMedCrossRef
19.
Zurück zum Zitat Cao Y, et al. B7-H1 overexpression regulates epithelial–mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res. 2011;71(4):1235–43.PubMedCrossRef Cao Y, et al. B7-H1 overexpression regulates epithelial–mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res. 2011;71(4):1235–43.PubMedCrossRef
20.
Zurück zum Zitat Raghow R, et al. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 2008;19(2):65–73.PubMedCrossRef Raghow R, et al. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 2008;19(2):65–73.PubMedCrossRef
21.
Zurück zum Zitat Pandey PR, et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. 2013;32(42):5111–22.PubMedCrossRef Pandey PR, et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. 2013;32(42):5111–22.PubMedCrossRef
Metadaten
Titel
PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma
verfasst von
Yiwei Wang
Hang Wang
Qi Zhao
Yu Xia
Xiaoyi Hu
Jianming Guo
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 8/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0655-2

Weitere Artikel der Ausgabe 8/2015

Medical Oncology 8/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.